Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells

Autor: TERRASI, Marianna, BAZAN, Viviana, CARUSO, Stefano, INSALACO, Lavinia, AMODEO, Valeria, FANALE, Daniele, CORSINI, Lidia Rita, CONTALDO, C, MERCANTI, A, FIORIO, E, LO RE, Giuseppe, CICERO, Giuseppe, SURMACZ, E, RUSSO, Antonio
Přispěvatelé: TERRASI, M, BAZAN, V, CARUSO, S, INSALACO, L, AMODEO, V, FANALE, D, CORSINI, LR, CONTALDO, C, MERCANTI, A, FIORIO, E, LO RE, G, CICERO, G, SURMACZ, E, Russo, A
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Leptin
Vascular Endothelial Growth Factor A
Physiology
Settore MED/06 - Oncologia Medica
Clinical Biochemistry
Ligands
chemistry.chemical_compound
Cell Movement
Promoter Regions
Genetic
skin and connective tissue diseases
Receptor
GENE-EXPRESSION
digestive
oral
and skin physiology
VEGF
Gene Expression Regulation
Neoplastic
Vascular endothelial growth factor
ROSIGLITAZONE
ACTIVATED-RECEPTOR-GAMMA
MCF-7 Cells
PIOGLITAZONE
Female
medicine.medical_specialty
Cell Survival
Sp1 Transcription Factor
BLADDER-CANCER
Breast Neoplasms
Biology
Benzophenones
Breast cancer
Ciglitazone
Internal medicine
medicine
Humans
RNA
Messenger
Viability assay
Binding Sites
Leptin receptor
Dose-Response Relationship
Drug
Cell Biology
IN-VITRO
medicine.disease
TRANSACTIVATION
DIABETIC-PATIENTS
PPAR gamma
Endocrinology
chemistry
Tyrosine
THIAZOLIDINEDIONES
Hormone
Popis: The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor γ (PPARγ) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPARγ to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.
Databáze: OpenAIRE
Externí odkaz: